𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Androgen Receptor and E2F-1 Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer

✍ Scribed by Kaseb, A. O.; Chinnakannu, K.; Chen, D.; Sivanandam, A.; Tejwani, S.; Menon, M.; Dou, Q. P.; Reddy, G. P.-V.

Book ID
121687235
Publisher
American Association for Cancer Research
Year
2007
Tongue
English
Weight
462 KB
Volume
67
Category
Article
ISSN
0008-5472

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Androgen receptor gene mutations in horm
Androgen receptor gene mutations in hormone-refractory prostate cancer
✍ WallοΏ½n, Mika J.; Linja, Marika; Kaartinen, Kaius; Schleutker, Johanna; Visakorpi πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 107 KB πŸ‘ 2 views

Prostate cancer is considered to be one of the most hormone-dependent human malignancies. As a key mediator of hormonal response, the androgen receptor (AR) is believed to have an important role in the progression of prostate cancer. Mutations in the coding region of the AR gene have been found in b

Emergence of metastatic hormone-refracto
Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy
✍ Edmund Chun Yu Lee; Martin P.R. Tenniswood πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 258 KB

## Abstract The anti‐androgens used in prostate cancer therapy have been designed to interfere with the normal androgen receptor (AR)‐mediated processes that ensure prostate cell survival, triggering tumor cells to undergo programmed cell death. While anti‐androgens were originally designed to trea